Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

BACKGROUND: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Ikeda, Satoshi, Kato, Terufumi, Ogura, Takashi, Sekine, Akimasa, Oda, Tsuneyuki, Masuda, Noriyuki, Igawa, Satoshi, Katono, Ken, Otani, Sakiko, Yamada, Kouzo, Saito, Haruhiro, Kondo, Tetsuro, Hosomi, Yukio, Nakahara, Yoshiro, Nishikawa, Masanori, Utumi, Keiko, Misumi, Yuki, Yamanaka, Takeharu, Sakamaki, Kentaro, Okamoto, Hiroaki
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://ncbi.nlm.nih.gov/pubmed/29499653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4150-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky